Itraconazole
Type of Medication: Antifungal
Indications: Treatment of ABPA in combination with steroids
Side Effects: GI upset ,nausea, abdo pain, dyspepsia, constipation, diarrhoea, headaches, raised liver enzymes, menstrual disorders, rash, pruritus, urticaria, angioedema. hepatitis and cholestasis (especially if treatment exceeds one month), peripheral neuropathy, Steven-Johnson syndrome, on prolonged use hypokalaemia, oedema and hair loss. Itraconazole is predominantly metabolised in the liver. The half-life of itraconazole is prolonged in both cirrhotic patients and individuals with renal insufficiency. A dose adjustment should be considered.Rare reports of heart faliure, caution in those patinets at risk and those patients recieving higher doses and longer treatment courses. Negative inotrope, has been associated with reports of congestive heart failure.
Route of administration: Adult (Oral)
Dose:5mg/kg/day in 2 divided doses (maximum 200 mg bd). Use liquid, capsules are not well absorbed in CF. Plama monitoring maybe required and dosage increased if necessary.
Administration: Itraconazole liquid contains 10mg per ml. Take on empty stomach (no food within 1 hour of taking) swish around mouth and swallow. Take for 4 weeks. Use with prednisolone when treating ABPA. Monitor liver function in patients receiving continuous treatment (more than one month).
Route of administration: Paediatric (Oral)
Dose:5 mg/kg/day in one or two divided doses. Max: 200 mg bd.
Examples of some Drug Interactions
Interacting drug: Antacids
Reduced absorption of itraconazole.
Interacting drug: Calcium channel blockers
Possible negative inotropic effect could be potentiated.
Interacting drug: Carbamazepine
dose,if co-administered with itraconazole, should be reduced if necessary.
Interacting drug: Ciclosporin,Tacrolimus,Sirolimus
increased plasma concentration .Dosage,if co-administered with itraconazole, may need to be reduced, Avoid concomitant use with sirolimus.
Interacting drug: Cisapride
Qt interval prologation. Avoid.
Interacting drug: Digoxin
increased plasma digoxin concentration.
Interacting drug: High dose inhaled steroids
there have been reports of adrenal suppression following the use of inhaled steroids and itraconazole
Interacting drug: Macrolides – clarithromycin and erythromycin
May increase plasma concentation of itraconazole.
Interacting drug: Methylprednisolone
increased plasma concentration of methylprednisolone.
Interacting drug: Midazolam
dose, if co-administered with itraconazole, should be reduced if necessary.
Interacting drug: Phenytoin
Reduced plasma concentration of itraconazole
Interacting drug: proton pump inhibitors
reduced absorption of itraconazole
Interacting drug: quinidine
plasma levels of quinidine elevated:increased risk of ventricular arrythmias.
Interacting drug: ranitidine and cimetidine
reduced absorption of itraconazole
Interacting drug: Rifampicin
Reduced plasma concentration of itraconazole
Interacting drug: sildenafil, tadalafil, vardenafil
increased plasma concentrations, dosage reduction may be required (sildenafil) or avoid concomitant use (vardenafil).
Interacting drug: simvastatin, atorvastatin
increased risk of myopathy;avoid concomitant use.
Interacting drug: Tolterodine
avoidance of itraconazole advised by manufacturer of tolterodone
Interacting drug: Warfarin
Effect of warfarin will be accentuated and the dose of warfarin should be reduced if necessary.
Interaction: Ivacaftor
Increases the dose of ivacaftor which must be reduced eg 1 tablet bd twice a week